Literature DB >> 21804388

p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.

Karoline Leonhardt1, Jens Einenkel, Sindy Sohr, Kurt Engeland, Lars-Christian Horn.   

Abstract

The objective of this study was to evaluate the role of the fimbriated end and nonfimbriated epithelium of fallopian tubes with regard to p53 signature, tubal intraepithelial lesions in transition (TILT), and serous tubal in-situ carcinoma (STIC) in cases of different kinds of serous pelvic cancer. This study immunohistochemically evaluated (by Ki-67 and p53 staining) the presence of p53 signature, TILT lesions, and STIC in 14 consecutive cases of prophylactic salpingo-oophorectomy in women with BRCA-1/2 mutation (bilateral salpingo-oophorectomy), 11 cases of macroscopically inconspicuous adnexae of patients with primary contralateral tubal cancer (TC), 9 cases of primary peritoneal cancer (PPC), and 10 cases of serous ovarian borderline tumors, evaluating the fallopian tubes (using the Sectioning and Extensively Examining the FIMbria protocol), ovarian surface epithelium, and ovarian cortical inclusion cysts. The frequencies of p53 signature, TILT, and STIC were 35.7%, 7.1%, and 0% in cases of prophylactic surgery, 18.2%, 9.1%, and 18.2% in TC, and 11.1%, 0%, and 33.3% in PPC. These precursor lesions were missed during the initial routine screening and were found in the fimbriated end of the fallopian tubes in 94%. In 1 case of PPC, staining for p53 was negative in STIC. The studied adnexal tissue of serous ovarian borderline tumor and ovarian cortical inclusion cysts of all cases showed no alterations according to p53 signature, TILT, or STIC. STIC and p53 signature as precursor lesions of pelvic serous cancer were seen in macroscopically inconspicuous contralateral fallopian tubes in unilateral TC, in patients with elective bilateral salpingo-oophorectomy, and in patients affected by PPC. Therefore, we propose the complete processing of adnexal tissue and the use of step sectioning to establish the correct diagnosis. Immunohistochemistry for p53 and ki-67 may aid in the diagnosis, but is not necessary for routine investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804388     DOI: 10.1097/PGP.0b013e318216d447

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  17 in total

Review 1.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

2.  Serous Tubal Carcinogenesis: The Recent Concept of Origin of Ovarian, Primary Peritoneal and Fallopian Tube High-Grade Serous Carcinoma.

Authors:  Tushar Kar; Asaranti Kar; Ipsita Dhal; Sasmita Panda; Priyadarshini Biswal; Bhagyalaxmi Nayak; Niranjan Rout; Sagarika Samantray
Journal:  J Obstet Gynaecol India       Date:  2017-06-01

Review 3.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

4.  Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma.

Authors:  Mary C Tolcher; Elizabeth M Swisher; Fabiola Medeiros; Joema F Lima; Jodi L Hilderbrand; Janis L Donovan; Rochelle L Garcia; William A Cliby; Sean C Dowdy
Journal:  Int J Gynecol Pathol       Date:  2015-01       Impact factor: 2.762

5.  Progestin Significantly Inhibits Carcinogenesis in the Mogp-TAg Transgenic Mouse Model of Fallopian Tube Cancer.

Authors:  Omar L Nelson; Rebecca Rosales; Jane M Turbov; Larry G Thaete; J Mark Cline; Gustavo C Rodriguez
Journal:  Cancer Prev Res (Phila)       Date:  2021-11-29

6.  E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.

Authors:  Na Lu Smith; Piri Welcsh; Joshua Z Press; Kathy J Agnew; Rochelle Garcia; Elizabeth M Swisher
Journal:  Genes Chromosomes Cancer       Date:  2012-08-09       Impact factor: 5.006

7.  Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.

Authors:  Marline G Harmsen; Marieke Arts-de Jong; Nicoline Hoogerbrugge; Angela H E M Maas; Judith B Prins; Johan Bulten; Steven Teerenstra; Eddy M M Adang; Jurgen M J Piek; Helena C van Doorn; Marc van Beurden; Marian J E Mourits; Ronald P Zweemer; Katja N Gaarenstroom; Brigitte F M Slangen; M Caroline Vos; Luc R C W van Lonkhuijzen; Leon F A G Massuger; Rosella P M G Hermens; Joanne A de Hullu
Journal:  BMC Cancer       Date:  2015-08-19       Impact factor: 4.430

Review 8.  Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.

Authors:  George U Eleje; Ahizechukwu C Eke; Ifeanyichukwu U Ezebialu; Joseph I Ikechebelu; Emmanuel O Ugwu; Onyinye O Okonkwo
Journal:  Cochrane Database Syst Rev       Date:  2018-08-24

Review 9.  Early preinvasive lesions in ovarian cancer.

Authors:  Gautier Chene; Gery Lamblin; Karine Le Bail-Carval; Philippe Chabert; Naoual Bakrin; Georges Mellier
Journal:  Biomed Res Int       Date:  2014-04-08       Impact factor: 3.411

Review 10.  Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.

Authors:  Ashwin R Sama; Russell J Schilder
Journal:  Int J Womens Health       Date:  2014-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.